ENVB SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 14, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 15, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 27, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 14, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 14, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 14, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Enveric Biosciences Reports Second Quarter 2026 Financial Results and Corporate Progress on EB-003

Aug 14, 2026

8-K

Enveric Biosciences Files Prospectus Supplement for $2.425 Million ATM Offering

Jun 9, 2026

8-K

Enveric Biosciences, Inc. Releases Q2 2026 Investor Presentation

Jun 8, 2026

8-K

Enveric Biosciences Adopts New Equity Award Agreements and Reports 2026 Annual Meeting Results

May 29, 2026

8-K

Enveric Biosciences Reports Q1 2026 Financial Results and Corporate Update

May 15, 2026

8-K

Enveric Biosciences Issues Proxy Supplement to Correct Reverse Stock Split Ratio

Apr 30, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

June 2026 ATM | Offering amount: $2,425,000 | Bank: H.C. Wainwright & Co.

Jun 9, 2026

424B3

SHARE RESALE REGISTRATION | Shares: 6,822,225 | Bank: H.C. Wainwright & Co., LLC

Apr 29, 2026

424B3

SHARE RESALE REGISTRATION | Shares: 680,620

Feb 18, 2026

424B5

February 2026 ATM | Offering amount: $1,346,000 | Bank: H.C. Wainwright & Co.

Feb 6, 2026

424B5

REGISTERED OFFERING

Jan 28, 2026

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 852,780 | Warrants amount: 882,627

Dec 31, 2025

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 29, 2026

Form D - Notice of Exempt Offering of Securities - Item 06b

May 4, 2026

S-3

SHARE RESALE REGISTRATION

Apr 23, 2026

Form D - Notice of Exempt Offering of Securities - Item 06b

Feb 11, 2026

S-1

SHARE RESALE REGISTRATION | Shares: 680,620

Feb 9, 2026

Form D - Notice of Exempt Offering of Securities - Item 06b

Dec 23, 2025

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 30, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 14, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 14, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Apr 3, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Oct 27, 2025

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Oct 10, 2025

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G

Sio Capital Management, LLC (Filed by)

Nov 3, 2026

SCHEDULE 13G/A

Lind Global Fund III LP (Filed by)

Aug 14, 2026

SCHEDULE 13G

ARMISTICE CAPITAL, LLC (Filed by)

Aug 14, 2026

SCHEDULE 13G/A

Ayrton Capital LLC (Filed by)

Aug 13, 2026

Coveney Kevin Michael (Reporting)

Jun 3, 2026

Tucker Joseph Edward (Reporting)

Jun 3, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Apr 30, 2026

CORRESP

Form CORRESP - Correspondence

Apr 28, 2026

LETTER

Form UPLOAD - SEC-generated letter

Apr 27, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Feb 18, 2026

CORRESP

Form CORRESP - Correspondence

Feb 17, 2026

LETTER

Form UPLOAD - SEC-generated letter

Feb 17, 2026

Enveric Biosciences, Inc. ENVB · SEC Filings